American Society of Clinical Oncology 47th Annual ... - ABCSG

Saturday, June 4, 2011Brd. 17Brd. 18Brd. 19Brd. 20Brd. 21Brd. 22Brd. 23Brd. 24Brd. 25A dose confirmation and signal-generating study of the immunocytokineL19-IL2 in combination with dacarbazine in patients with metastaticmelanoma. (Abstract #2531)T. K. Eigentler, B. Weide, G. Spitaleri, F. G. De Braud, A. Romanini,R. Gonzales-Inglesias, A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato,M. Kaspar, E. Trachsel, D. Neri, H. D. Menssen, C. GarbeMonitoring T-cell responses in a phase II study of AGS-003, an autologousdendritic cell–based therapy in patients with newly diagnosed advancedstage renal cell carcinoma in combination with sunitinib. (Abstract #2532)R. A. Figlin, A. Amin, A. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein,M. DeBenedette, S. K. Pal, V. Master, I. Y. Tcherepanova, R. Jain, W. L. Williams,T. Monesmith, F. Miesowicz, C. A. NicoletteA dendritic cell–based vaccine effects on T-cell responses compared with aviral vector vaccine when administered to patients following resection ofcolorectal metastases in a randomized phase II study. (Abstract #2533)H. K. Lyerly, A. Hobeika, D. Niedzwiecki, T. Osada, J. Marshall, C. R. Garrett,D. Z. Chang, M. Aklilu, T. S. Crocenzi, D. J. Cole, S. Dessureault,S. D. Hsu, A. Bulusu, B. M. Clary, R. Annechiarico, G. Devi,V. Chadaram, T. M. Clay, M. MorseLymphodepletion and tumor burden govern clinical responses in patientswith B-cell malignancies treated with autologous, CD19-targeted T cells.(Abstract #2534)R. J. Brentjens, I. Riviere, J. Park, M. Davilla, X. Wang, R. Yeh, N. Lamanna,M. G. Frattini, M. SadelainA feasibility study of combination therapy with trastuzumab (T),cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumorvaccine for the treatment of HER2 metastatic breast cancer. (Abstract#2535)L. A. Emens, R. Gupta, S. Petrik, M. Laiko, J. M. Leatherman, J. Levi,J. M. Asquith, M. M. Daphtary, E. Garrett-Mayer, B. J. Kobrin, N. E. Davidson,T. Dauses, S. Atay-Rosenthal, X. Ye, A. C. Wolff, V. Stearns, E. M. JaffeeAn umbrella protocol for histology-independent, phase I modular studybased on EGFR mutation status: Using erlotinib alone or in combination withcetuximab, bortezomib, or dasatinib to overcome resistance. (Abstract#2536)J. Fok, R. Kurzrock, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, F. Janku,G. S. Falchook, S. A. Piha-Paul, R. Katz, S. Fu, S. L. Moulder, J. J. WhelerPhase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8)agonist, in patients with advanced solid tumors. (Abstract #2537)P. A. Cohen, D. W. Northfelt, G. J. Weiss, D. D. Von Hoff, K. Manjarrez, G. Dietsch,R. M. Hershberg, R. K. RamanathanPhase I study of TAK-285, an investigational HER2/EGFR inhibitor, inpatients (pts) with advanced cancer: Updated results and assessment ofhuman CSF distribution. (Abstract #2538)E. G. Chiorean, E. A. Sausville, E. I. Heath, A. Weise, J. Gomez-Navarro,K. Venkatakrishnan, S. Sankoh, J. Wu, M. Corvez, P. LoRussoDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as apharmacodynamic (PD) biomarker in phase I trials of the humanizedmonoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A). (Abstract #2539)J. Fredrickson, I. Chang, M. Friesenhahn, E. Ashton, P. N. Munster, M. S. Gordon,D. S. Chen, L. Naumovski, A. de Crespigny, L. S. RosenSATURDAY131